nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.06.2015 | Original Article

[¹⁸F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 7/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Visualization of the spatial distribution of neurofibrillary tangles would help in the diagnosis, prevention and treatment of dementia. The purpose of the study was to evaluate the clinical utility of [¹⁸F]THK-5117 as a highly selective tau imaging radiotracer.

Methods

We initially evaluated in vitro binding of [³H]THK-5117 in post-mortem brain tissues from patients with Alzheimer’s disease (AD). In clinical PET studies, [¹⁸F]THK-5117 retention in eight patients with AD was compared with that in six healthy elderly controls. Ten subjects underwent an additional [¹¹C]PiB PET scan within 2 weeks.

Results

In post-mortem brain samples, THK-5117 bound selectively to neurofibrillary deposits, which differed from the binding target of PiB. In clinical PET studies, [¹⁸F]THK-5117 binding in the temporal lobe clearly distinguished patients with AD from healthy elderly subjects. Compared with [¹¹C]PiB, [¹⁸F]THK-5117 retention was higher in the medial temporal cortex.

Conclusion

These findings suggest that [¹⁸F]THK-5117 provides regional information on neurofibrillary pathology in living subjects.

Nur mit Berechtigung zugänglich

Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.CrossRefPubMed

Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A. 1985;82:4245–9.CrossRefPubMedCentralPubMed

Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084–9.PubMed

Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913–7.CrossRefPubMedCentralPubMed

Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351–7.CrossRefPubMed

Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer’s disease. Arch Neurol. 1995;52:81–8.CrossRefPubMed

Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol. 1997;41:17–24. doi:10.1002/ana.410410106.CrossRefPubMed

Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42:631–9.CrossRefPubMed

Wilcock GK, Esiri MM. Plaques, tangles and dementia. A quantitative study. J Neurol Sci. 1982;56:343–56.CrossRefPubMed

10.

Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex. 1991;1:103–16.CrossRefPubMed

11.

Gotz J, Ittner A, Ittner LM. Tau-targeted treatment strategies in Alzheimer’s disease. Br J Pharmacol. 2012;165:1246–59. doi:10.1111/j.1476-5381.2011.01713.x.CrossRefPubMedCentralPubMed

12.

Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem Pharmacol. 2014;88:529–39. doi:10.1016/j.bcp.2013.12.008.CrossRefPubMed

13.

Citron M. Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9:387–98. doi:10.1038/nrd2896.CrossRefPubMed

14.

Takashima A. Tau aggregation is a therapeutic target for Alzheimer’s disease. Curr Alzheimer Res. 2010;7:665–9.CrossRefPubMed

15.

Jack Jr CR, Holtzman DM. Biomarker modeling of Alzheimer’s disease. Neuron. 2013;80:1347–58. doi:10.1016/j.neuron.2013.12.003.CrossRefPubMedCentralPubMed

16.

Cummings JL. Biomarkers in Alzheimer’s disease drug development. Alzheimers Dement. 2011;7:e13–44. doi:10.1016/j.jalz.2010.06.004.CrossRefPubMed

17.

Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer’s disease. Ann Neurol. 1995;38:649–52. doi:10.1002/ana.410380414.CrossRefPubMed

18.

Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H, Hampel H, et al. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease. Ann Neurol. 2001;50:150–6.CrossRefPubMed

19.

Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease. Alzheimers Dement. 2013;9:666–76. doi:10.1016/j.jalz.2012.11.008.CrossRefPubMed

20.

Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457–68. doi:10.3233/JAD-122059.PubMed

21.

Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu FR, Xia CF, et al. Early clinical PET imaging results with the novel PHF-Tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171–84. doi:10.3233/Jad-130098.PubMed

22.

Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094–108. doi:10.1016/j.neuron.2013.07.037.CrossRefPubMed

23.

Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, et al. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain. 2011;134:1089–100. doi:10.1093/brain/awr038.CrossRefPubMed

24.

Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420–7. doi:10.2967/jnumed.112.117341.CrossRefPubMed

25.

Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2014;41:816–26. doi:10.1007/s00259-013-2681-7.CrossRefPubMed

26.

Okamura N, Suemoto T, Furumoto S, Suzuki M, Shimadzu H, Akatsu H, et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer’s disease. J Neurosci. 2005;25:10857–62. doi:10.1523/JNEUROSCI. 1738-05.2005.CrossRefPubMed

27.

Harada R, Okamura N, Furumoto S, Tago T, Maruyama M, Higuchi M, et al. Comparison of the binding characteristics of [18F]THK-523 and other amyloid imaging tracers to Alzheimer’s disease pathology. Eur J Nucl Med Mol Imaging. 2013;40:125–32.CrossRefPubMed

28.

Okamura N, Furumoto S, Fodero-Tavoletti MT, Mulligan R, Harada R, Yates P, et al. Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014;137:1762–71.CrossRefPubMed

29.

Kitamoto T, Ogomori K, Tateishi J, Prusiner SB. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest. 1987;57:230–6.PubMed

30.

Murayama H, Shin RW, Higuchi J, Shibuya S, Muramoto T, Kitamoto T. Interaction of aluminum with PHFtau in Alzheimer’s disease neurofibrillary degeneration evidenced by desferrioxamine-assisted chelating autoclave method. Am J Pathol. 1999;155:877–85.CrossRefPubMedCentralPubMed

31.

Verdurand M, Bort G, Tadino V, Bonnefoi F, Le Bars D, Zimmer L. Automated radiosynthesis of the Pittsburg compound-B using a commercial synthesizer. Nucl Med Commun. 2008;29:920–6. doi:10.1097/MNM.0b013e328304e0e1.CrossRefPubMed

32.

Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab. 1992;12:571–83. doi:10.1038/jcbfm.1992.81.CrossRefPubMed

33.

Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD, et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology. 2008;71:743–9. doi:10.1212/01.wnl.0000324924.91351.7d.CrossRefPubMedCentralPubMed

34.

Hof PR, Bierer LM, Perl DP, Delacourte A, Buee L, Bouras C, et al. Evidence for early vulnerability of the medial and inferior aspects of the temporal lobe in an 82-year-old patient with preclinical signs of dementia. Regional and laminar distribution of neurofibrillary tangles and senile plaques. Arch Neurol. 1992;49:946–53.CrossRefPubMed

35.

Kuzuhara S, Ihara Y, Toyokura Y, Shimada H. A semiquantitative study on Alzheimer neurofibrillary tangles demonstrated immunohistochemically with anti-tau antibodies, in the brains of non-demented and demented old people. No To Shinkei. 1989;41:465–70.PubMed

36.

Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer’s disease. Ann Neurol. 1999;45:358–68.CrossRefPubMed

37.

Morris JC, Price JL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer’s disease. J Mol Neurosci. 2001;17:101–18.CrossRefPubMed

38.

Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24–35.CrossRefPubMed

39.

Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2006;355:2652–63. doi:10.1056/NEJMoa054625.CrossRefPubMed

40.

Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease. J Neurosci. 2001;21:RC189.PubMed

41.

Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer’s disease. Lancet Neurol. 2011;10:667–70. doi:10.1016/S1474-4422(11)70123-5.CrossRefPubMed

42.

Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29. doi:10.1002/ana.22068.CrossRefPubMed

Titel: [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease
Publikationsdatum: 01.06.2015
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 7/2015
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-3035-4

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2015

Biodistribution and radiation dosimetry of 82Rb at rest and during peak pharmacological stress in patients referred for myocardial perfusion imaging

Ursodeoxycholic acid versus phenobarbital pretreatment prior to hepatobiliary scintigraphy in neonatal cholestasis: is it time for shifting gears towards a practice change?

All-in-one interictal presurgical imaging in patients with epilepsy: single-session EEG/PET/(f)MRI

Kewal K. Jain: Applications of Biotechnology in Oncology

Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?

Prognostic value of volume-based measurements on 11C-methionine PET in glioma patients